Bildkälla: Stockfoto

Amniotics Q4 2023: Investigator-sponsored trial in lung transplantation needs funding - Redeye

Redeye comments on Amniotics’ Q4 report. The company will need funding before it can start an investigator-sponsored clinical trial in lung transplantation with PulmoStem, its lead stem-cell candidate. However, the company is in a problematic financial situation.

Redeye comments on Amniotics’ Q4 report. The company will need funding before it can start an investigator-sponsored clinical trial in lung transplantation with PulmoStem, its lead stem-cell candidate. However, the company is in a problematic financial situation.
Börsvärldens nyhetsbrev
ANNONSER